Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline
Summary
Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control.
The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), beta-blockers, renin inhibitors, and diuretics. The percentage of patients treated using monotherapy and combination therapy (including fixed-dose combinations) varies from country to country. The most commonly prescribed drugs in the CCB class are amlodipine and lercanidipine, while the leading ARBs are telmisartan, candesartan, olmesartan, irbesartan, losartan, valsartan, azilsartan medoxomil, and eprosartan. Ramipril, imidapril, perindopril, enalapril, lisinopril, benazepril, fosinopril, trandolapril, and quinapril dominate the ACEIs.
Scope
- Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
- Will generics continue to dominate treatment?
- How do the elderly populations and their associated risk factors affect prevalence?
- The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules in various stages of development, dominated by small molecules.
- Will the upcoming molecules change the treatment paradigm in the near future?
- How will the weak pipeline affect the market?
- Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
- Over the 2014–2021 forecast period, the APAC anti-hypertensive therapeutics market is expected to increase in value at a CAGR of 3.4% from $15.7 billion to just over $19.9 billion. Growth is projected to vary considerably across the four assessed markets.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will branded products’ patent expirations pose a significant threat?
- Will new market entrants over the forecast period lead to substantial changes in annual therapy costs?
Reasons to buy
This report will enable you to -
- Understand the clinical context of hypertension by considering symptoms, etiology, pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape, and recognize gaps.
- Appreciate key anti-hypertensive pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in anti-hypertensive clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for the China, India, Australia, and Japan.
- Discover trends in licensing and co-development deals concerning anti-hypertensive products and identify the major strategic consolidations that have shaped the commercial landscape.
Table Of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Pathophysiology 9
2.2 Etiology 10
2.3 Signs and Symptoms 11
2.4 Co-morbidities and Complications 11
2.5 Diagnosis 13
2.5.1 Office or Clinic Blood Pressure Monitoring 13
2.5.2 Ambulatory Blood Pressure Monitoring 14
2.5.3 Home Blood Pressure Monitoring 14
2.5.4 Miscellaneous Methods 14
2.5.5 Diagnosis of Target Organ Damage 14
2.5.6 Diagnosis of Hypertension in Pregnancy 15
2.6 Classification 15
2.7 Epidemiology 16
2.8 Prognosis 17
2.9 Treatment and Management 17
2.9.1 Treatment Strategy 19
3 Marketed Products 26
3.1 Key Marketed Products 26
3.1.1 Prestalia (perindopril arginine + amlodipine besylate) 26
3.1.2 Azilva (azilsartan medoxomil) 26
3.1.3 Amlodipine besylate 26
3.1.4 Telmisartan 27
3.1.5 Aliskiren 28
3.1.6 Olmesartan medoxomil 29
3.1.7 Valsartan 30
3.1.8 Losartan 31
3.1.9 Exforge (amlodipine + valsartan) 32
3.2 Heat Map for Marketed Products 33
4 Anti-hypertensive Market to 2021 – Pipeline Products 35
4.1 Overall Pipeline 35
4.1.1 Pipeline Analysis by Molecule Type 36
4.1.2 Pipeline Analysis by Mechanism of Action 37
4.2 Clinical Trial Analysis 39
4.2.1 Failure Rate 39
4.2.2 Clinical Trial Size 41
4.2.3 Duration 42
4.3 Promising Drug Candidates in Pipeline 43
4.3.1 SER-100 43
4.3.2 CS-3150 43
5 Market Forecast to 2021 44
5.1 Asia-Pacific Market 44
5.1.1 Treatment Use Patterns 45
5.1.2 Market Size 46
5.2 Australia 47
5.2.1 Treatment Use Patterns 47
5.2.2 Annual Cost of Therapy 47
5.2.3 Market Size 48
5.3 India 49
5.3.1 Treatment Use Patterns 49
5.3.2 Annual Cost of Therapy 49
5.3.3 Market Size 50
5.4 China 51
5.4.1 Treatment Use Patterns 51
5.4.2 Annual Cost of Therapy 51
5.4.3 Market Size 52
5.5 Japan 53
5.5.1 Treatment Use Patterns 53
5.5.2 Annual Cost of Therapy 53
5.5.3 Market Size 54
5.6 Drivers and Barriers 55
5.6.1 Drivers 55
5.6.2 Barriers 56
6 Deals and Strategic Consolidations 57
6.1 Licensing Agreements 57
6.1.1 Major Licensing Deals 59
6.2 Co-development Agreements 60
6.2.1 Major Co-development Agreements 62
7 Appendix 63
7.1 All Pipeline Drugs by Phase 63
7.1.1 Discovery 63
7.1.2 Preclinical 64
7.1.3 Phase I 66
7.1.4 Phase II 68
7.1.5 Phase III 69
7.2 Market Forecasts to 2021 70
7.2.1 Asia-Pacific 70
7.2.2 China 70
7.2.3 India 70
7.2.4 Japan 71
7.2.5 Australia 71
7.3 Market Definitions 71
7.4 Abbreviations 72
7.5 References 74
7.6 Research Methodology 78
7.6.1 Coverage 78
7.6.2 Secondary Research 78
7.6.3 Primary Research 79
7.6.4 Therapeutic Landscape 79
7.6.5 Geographical Landscape 81
7.6.6 Pipeline Analysis 82
7.7 Expert Panel Validation 82
7.8 Contact Us 82
7.9 Disclaimer 82
List Of Tables
1.1 List of Tables
Table 1: Anti-hypertensive Therapeutics, Possible Co-morbidities 12
Table 2: Anti-hypertensive Therapeutics, Proposal for Outcome-Driven Reference Values for Ambulatory Blood Pressure Measurement (mmHg) 14
Table 3: Anti-hypertensive Therapeutics, Blood Pressure Classification in Adults (mmHg) 15
Table 4: Anti-hypertensive Therapeutics, Definitions of Hypertension by Office and Out-of-Office Blood Pressure Levels (mmHg) 16
Table 5: Anti-hypertensive Therapeutics, Prevalence of Hypertension 17
Table 6: Anti-hypertensive Therapeutics, Suggested Medications for Hypertensive Patients with Certain Medical Conditions 18
Table 7: Anti-hypertensive Therapeutics, Lifestyle Measures and Recommendations 19
Table 8: Anti-hypertensive Therapeutics, Compelling and Possible Contra-indications of Anti-hypertensive Drugs 24
Table 9: Anti-hypertensive Therapeutics, Preference of Drug in Specific Condition/Situation of Hypertensive Patients 25
Table 10: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Discovery, 2015 63
Table 11: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Preclinical, 2015 64
Table 12: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase I, 2015 66
Table 13: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase II, 2015 68
Table 14: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase III, 2015 69
Table 15: Anti-hypertensive Therapeutics, Asia-Pacific, Market Forecast, 2014–2021 70
Table 16: Anti-hypertensive Therapeutics , China, Market Forecast, 2014–2021 70
Table 17: Anti-hypertensive Therapeutics , India, Market Forecast, 2014–2021 70
Table 18: Anti-hypertensive Therapeutics , Japan, Market Forecast, 2014–2021 71
Table 19: Anti-hypertensive Therapeutics , Australia, Market Forecast, 2014–2021 71
Table 20: Abbreviations 72
List Of Figures
1.2 List of Figures
Figure 1: Anti-hypertensive Therapeutics, Physiological Mechanism of Renin Angiotensin Aldosterone System 10
Figure 2: Anti-hypertensive Therapeutics, Global, Prevalence Rate (%), 2007–2010 16
Figure 3: Anti-hypertensive Therapeutics, Treatment Algorithm of Hypertension 18
Figure 4: Anti-hypertensive Therapeutics, Influence of Drugs on the Renin Angiotensin Aldosterone System 22
Figure 5: Anti-hypertensive Therapeutics, Treatment Algorithm, 2014 23
Figure 6: Anti-hypertensive Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products, 2015 34
Figure 7: Anti-hypertensive Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2015 35
Figure 8: Anti-hypertensive Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2015 36
Figure 9: Anti-hypertensive Therapeutics, Global, Pipeline by Mechanism of Action, 2015 38
Figure 10: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate (%), 2015 40
Figure 11: Anti-hypertensive Therapeutics, Global, Clinical Trial Size, 2015 41
Figure 12: Anti-hypertensive Therapeutics, Global, Clinical Trial Duration (months), 2015 42
Figure 13: Anti-hypertensive Therapeutics, Asia-Pacific, Treatment Use Patterns, Patients (million), 2014–2021 45
Figure 14: Anti-hypertensive Therapeutics, Asia-Pacific, Market Size ($bn), 2014–2021 46
Figure 15: Anti-hypertensive Therapeutics, Australia, Treatment Use Patterns, Patients (million), 2014–2021 47
Figure 16: Anti-hypertensive Therapeutics, Australia, Annual Cost of Therapy ($), 2014–2021 48
Figure 17: Anti-hypertensive Therapeutics, Australia, Market Size ($bn), 2014–2021 48
Figure 18: Anti-hypertensive Therapeutics, India, Treatment Use Patterns, Patients (million), 2014–2021 49
Figure 19: Anti-hypertensive Therapeutics, India, Annual Cost of Therapy ($), 2014–2021 50
Figure 20: Anti-hypertensive Therapeutics, India, Market Size ($bn), 2014–2021 50
Figure 21: Anti-hypertensive Therapeutics, China, Treatment Use Patterns, Patients (million), 2014–2021 51
Figure 22: Anti-hypertensive Therapeutics, China, Annual Cost of Therapy ($), 2014–2021 52
Figure 23: Anti-hypertensive Therapeutics, China, Market Size ($bn), 2014–2021 52
Figure 24: Anti-hypertensive Therapeutics, Japan, Treatment Use Patterns (million), 2014–2021 53
Figure 25: Anti-hypertensive Therapeutics, Japan, Annual Cost of Therapy ($), 2014–2021 54
Figure 26: Anti-hypertensive Therapeutics, Japan, Market Size ($bn), 2014–2021 54
Figure 27: Anti-hypertensive Therapeutics, Global, Licensing Deals by Region, Phase and Value, 2006– Q1 2015 57
Figure 28: Anti-hypertensive Therapeutics, Global, Licensing Deals by Phase and Mechanism of Action, 2006–Q1 2015 58
Figure 29: Anti-hypertensive Therapeutics, Global, Licensing Deals by Geography, 2006–Q1 2015 59
Figure 30: Anti-hypertensive Therapeutics, Global, Co-development Deals by Region, Value and Phase, 2006– Q1 2015 60
Figure 31: Anti-hypertensive Therapeutics, Global, Co-development Deals by Phase and Mechanism of Action, 2006–Q1 2015 61
Figure 32: Anti-hypertensive Therapeutics, Global, Co-development Deals by Geography, 2006–Q1 2015 62
Figure 33: GBI Research Market Forecasting Model (Example) 81
